

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

HCC1954

RRID:CVCL_1259

Type: Cell Line

Proper Citation

RRID:CVCL_1259

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1259

Proper Citation: RRID:CVCL_1259

Description: Cell line HCC1954 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:9833771](#), [PMID:11314036](#), [PMID:16959974](#), [PMID:17157791](#), [PMID:17932254](#), [PMID:19582160](#), [PMID:20070913](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21378333](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:23637631](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:28889351](#), [PMID:29273624](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: East Indian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1954

Synonyms: HCC-1954, Hamon Cancer Center 1954

Cross References: BTO:BTO_0005368, CLO:CLO_0003647, EFO:EFO_0001175, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ATCC:CRL-2338, BCRJ:0280, BioGRID_ORCS_Cell_line:425, BioSample:SAMN03473018, BioSample:SAMN10987850, cancercellines:CVCL_1259, Cell_Model_Passport:SIDM00872, ChEMBL-Cells:ChEMBL3308107, ChEMBL-Targets:ChEMBL1075459, CLS:305268, Cosmic:749709, Cosmic:904369, Cosmic:1136367, Cosmic:1235077, Cosmic:1287889, Cosmic:1308993, Cosmic:1430345, Cosmic:1473150, Cosmic:1518107, Cosmic:1603208, Cosmic:1717243, Cosmic:1935009, Cosmic:1995428, Cosmic:2165007, Cosmic-CLP:749709, DepMap:ACH-000859, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:749709, GEO:GSM185081, GEO:GSM185082, GEO:GSM186724, GEO:GSM217578, GEO:GSM219962, GEO:GSM274675, GEO:GSM303673, GEO:GSM303675, GEO:GSM303680, GEO:GSM303682, GEO:GSM303684, GEO:GSM303687, GEO:GSM303689, GEO:GSM303691, GEO:GSM303695, GEO:GSM303698, GEO:GSM303700, GEO:GSM303704, GEO:GSM303707, GEO:GSM303709, GEO:GSM303712, GEO:GSM303715, GEO:GSM303719, GEO:GSM303721, GEO:GSM303723, GEO:GSM303726, GEO:GSM303729, GEO:GSM303731, GEO:GSM303735, GEO:GSM303738, GEO:GSM303740, GEO:GSM303742, GEO:GSM303745, GEO:GSM303747, GEO:GSM303750, GEO:GSM303753, GEO:GSM303754, GEO:GSM303760, GEO:GSM303762, GEO:GSM303766, GEO:GSM303769, GEO:GSM303770, GEO:GSM303775, GEO:GSM303777, GEO:GSM303780, GEO:GSM303784, GEO:GSM303786, GEO:GSM303789, GEO:GSM337683, GEO:GSM337684, GEO:GSM337685, GEO:GSM337686, GEO:GSM337687, GEO:GSM337688, GEO:GSM337689, GEO:GSM337690, GEO:GSM337691, GEO:GSM337692, GEO:GSM337693, GEO:GSM337694, GEO:GSM337695, GEO:GSM344374, GEO:GSM344424, GEO:GSM350499, GEO:GSM481299, GEO:GSM718290, GEO:GSM783937, GEO:GSM847341, GEO:GSM847483, GEO:GSM887046, GEO:GSM888116, GEO:GSM1008901, GEO:GSM1053712, GEO:GSM1172871, GEO:GSM1172962, GEO:GSM1215272, GEO:GSM1374508, GEO:GSM1374509, GEO:GSM1401665, GEO:GSM1669852, GEO:GSM2258830, GEO:GSM2258831, GEO:GSM2258832, GEO:GSM2258833, GEO:GSM2258834, GEO:GSM2258835, GEO:GSM2258836, GEO:GSM2258837, GEO:GSM2258838, GEO:GSM2258839, GEO:GSM2258840, GEO:GSM2258841, GEO:GSM2258842, GEO:GSM2258843, GEO:GSM2258844, GEO:GSM2258845, GEO:GSM2258846, GEO:GSM2258847, GEO:GSM2258929, GEO:GSM2258930, GEO:GSM2258931, GEO:GSM3258551, IARC_TP53:21363, IGRhCellID:HCC1954, KCLB:9S1954, LiGeA:CCLE_705, LINCS_HMS:50213, LINCS_LDP:LCL-1332, Lonza:1357, PharmacDB:HCC1954_486_2019, PRIDE:PXD002486, PRIDE:PXD005339, PRIDE:PXD030304, Progenetix:CVCL_1259, PubChem_Cell_line:CVCL_1259, SLKBase:3543, Wikidata:Q54881618

ID: CVCL_1259

Record Creation Time: 20220427T220318+0000

Record Last Update: 20260905T180218+0000

Ratings and Alerts

No rating or validation information has been found for HCC1954.

No alerts have been found for HCC1954.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 594 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pougoue Ketchemen J, et al. (2026) Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer. British journal of cancer, 134(12), 1820.

Kopp A, et al. (2026) In Vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies. Molecular cancer therapeutics, 25(4), 610.

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer research, 86(6), 1467.

Tang S, et al. (2026) PTEN Loss Promotes PI3K γ Phosphorylation and EPHA2/SRC/p-PI3K γ Y962 Complex Assembly to Drive Tumorigenesis. Cancer discovery, 16(3), 521.

Caire R, et al. (2026) A 3D morphogenetic blueprint for metastatic outgrowth in breast cancer. Cell, 189(12), 3701.

Boz AB, et al. (2026) AXL-Driven Stemness and Hedgehog Signaling in HER2-Positive Breast Cancer with Acquired Trastuzumab Resistance: Synergistic Potential of AXL and HER2 Co-Targeting. Life (Basel, Switzerland), 16(3).

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell reports, 45(2), 116882.

Rampa DR, et al. (2026) Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(8), 1454.

Ishida M, et al. (2026) AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. NPJ precision oncology, 10(1).

Wang X, et al. (2026) Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. Cell reports. Medicine, 7(7), 102885.

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. *Molecular oncology*.

Maurya SK, et al. (2025) Mucin 5AC Promotes Breast Cancer Brain Metastasis through cMET/CD44v6. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 921.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. *Cell reports. Medicine*, 6(12), 102478.

Malvi P, et al. (2025) PDE7A inhibition suppresses triple-negative breast cancer by attenuating de novo pyrimidine biosynthesis. *Cell reports. Medicine*, 6(9), 102356.

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. *Cell chemical biology*.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. *Cell reports. Medicine*, 6(11), 102446.

Ma J, et al. (2025) Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers. *Cellular oncology (Dordrecht, Netherlands)*, 48(6), 1837.

Cheng TC, et al. (2025) Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4-overexpressing breast cancer cells. *International journal of cancer*, 156(8), 1606.

Schram AM, et al. (2025) The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(23), 4933.

Manupati K, et al. (2025) Novel Metastasis Suppressor PI3KC2 γ Is Mediated by mTORC1 Signaling in Breast Cancer. *Molecular cancer research : MCR*, 23(9), 765.